Why Is Epinephrine Preferred for Cardiac Arrest? The Answer May Lie in β₂-Adrenergic Receptor Activation

Area of Science:

• Cardiology
• Pharmacology
• Emergency Medicine

Background:

• Epinephrine (Epi) is a primary treatment for cardiac arrest during cardiopulmonary resuscitation (CPR) per advanced life support (ALS) guidelines.
• The specific pharmacological advantages of Epi over other vasopressors in CPR are not fully understood.

Purpose of the Study:

• To explore the unique pharmacological properties of epinephrine (Epi) that may enhance its efficacy during cardiopulmonary resuscitation (CPR).
• To highlight the critical role of beta-2 adrenergic receptor (β2AR) activation by Epi in improving cardiac function and patient outcomes during cardiac arrest.

Main Methods:

• This is an opinion article, presenting a theoretical argument based on existing pharmacological knowledge.
• The article focuses on comparing the mechanisms of action of Epi with other vasopressors, particularly norepinephrine (NE).

Main Results:

• Epinephrine uniquely activates the beta-2 adrenergic receptor (β2AR), a property not shared by other vasopressors like norepinephrine (NE).
• β2AR activation by Epi enhances pacemaker cell pulse generation and restores contractile function in ischemic cardiomyocytes through sodium/potassium pump activation.
• These β2AR-mediated effects provide Epi with superior capabilities for improving cardiac output and tissue perfusion compared to other vasopressors.

Conclusions:

• The β2AR activation by epinephrine is a key factor differentiating its efficacy in CPR from other vasopressors.
• Epinephrine's distinct pharmacological profile makes it particularly valuable in situations where simple blood pressure elevation is insufficient, such as during cardiac arrest.